Parameters Used for Evaluation of the Response to Treatment with Recombinant Human Growth Hormone in Paediatric and Adult Populations in Poland: Review
DOI:
https://doi.org/10.12775/JEHS.2025.81.59965Keywords
growth hormone, growth hormone deficiency, recombinant human growth hormone therapyAbstract
Introduction and purpose
Recombinant human growth hormone (rhGH) therapy has been the standard treatment for paediatric short stature for many years, and a therapeutic option for the replacement therapy of growth hormone deficiency in the post-growth patient population. Each country providing rhGH treatment has its own programms based on national recommendations and international guidelines. The aim of this review was to discuss selected parameters used for assessment of the response to rhGH treatment in the paediatric and the post-growth adult populations, using the example of Poland.
Description of state of knowledge
The rhGH therapy requires thorough monitoring to minimize potential adverse effects and to optimize treatment outcomes. Due to the differences in the final therapeutic effects of rhGH between pediatric and adult cohorts, different parameters are used to assess treatment efficacy.
In children and adolescents, anthropometric measurements reflecting growth are primarily utilized. Considering the systemic effects of the rhGH, metabolic parameters are evaluated in both populations. In adults, additional assessments include quality of life, measured using standardized questionnaires, and bone mineral density. Computer predictive models can also be used to monitor the treatment.
Conclusion
Growth hormone therapy has been associated with a range of well-documented benefits both paediatric and adult populations. However, its administration necessitates comprehensive monitoring based on standardized parameters specific to each patient cohort.
References
1. Ranke MB, Wit JM. Growth hormone — past, present and future. Nat Rev Endocrinol. 2018;14(5):285-300. doi:10.1038/nrendo.2018.22
2. Ho KKY. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, . Eur J Endocrinol. 2007;157(6):695-700. doi:10.1530/EJE-07-0631
3. Johannsson G, Touraine P, Feldt-Rasmussen U, et al. Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients. J Clin Endocrinol Metab. 2022;107(7):1906-1919. doi:10.1210/clinem/dgac199
4. Bamba V, Kanakatti Shankar R. Approach to the Patient: Safety of Growth Hormone Replacement in Children and Adolescents. J Clin Endocrinol Metab. 2022;107(3):847-861. doi:10.1210/clinem/dgab746
5. Treatment of Severe Growth Hormone Deficiency in Adult and Adolescent Patients After Completion of Growth-promoting Therapy (ICD-10 E23.0). Notice of the Minister of Health of 19 March 2025 on the list of reimbursed medicines, foodstuffs. Available from: https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.gov.pl/attachment/622d9b89-9988-494e-9f1d-3c7497388c13&ved=2ahUKEwjYl9aynaWMAxXyEhAIHVJoO9UQFnoECBQQAQ&usg=AOvVaw0_8qOa-EnVgVHz11htZj1d . (Accessed on 30.03.2025)
6. Treatment of Short-Statured Children with Chronic Kidney Failure (ICD-10 N18). Notice of the Minister of Health of 19 March 2025 on the List of Reimbursed Medicines, Foodstuffs for Special Medical Purposes, and Medical Devices. Available from: https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.archiwum.mz.gov.pl/wp-content/uploads/2014/11/B.38._nowy-od-07.2014.docx&ved=2ahUKEwjxgPjknKWMAxWgAxAIHQIiCdMQFnoECBcQAQ&usg=AOvVaw0ZFyVnqQ_JPQ6cwfqiRoop. (Accessed on 30.03.2025)
7. Treatment of Short-Statured Children with Turner Syndrome (ICD-10 Q96). Notice of the Minister of Health of 19 March 2025 on the List of Reimbursed Medicines, Foodstuffs for Special Medical Purposes, and Medical Devices. Available from: https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.gov.pl/attachment/24fb030d-07ac-44a5-afbb-866296323384&ved=2ahUKEwiC8cDLnKWMAxWsKhAIHWmWHdYQFnoECBcQAQ&usg=AOvVaw3j-jJgftOb6LSuyAOwqe0L. (Accessed on 30.03.2025)
8. Treatment of Short-Statured Children with Somatotropic Pituitary Insufficiency (ICD-10 E23). Notice of the Minister of Health of 19 March 2025 on the List of Reimbursed Medicines, Foodstuffs for Special Medical Purposes, and Medical Devices. Available from: https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.gov.pl/attachment/c2022097-fbd3-43fc-8629-f968b509df5f&ved=2ahUKEwi_ityTnKWMAxWkBxAIHd1KNtgQFnoECBcQAQ&usg=AOvVaw3eqIDwKJ_0tb93GVltt7OZ. (Accessed on 30.03.2025)
9. Growth Hormone Treatment of Short-Statured Children Born Small for Gestational Age (SGA) or with Intrauterine Growth Restriction (IUGR) (ICD-10 R62.9). Notice of the Minister of Health of 19 March 2025 on the List of Reimbursed Medicines, Foodstuffs for Special Medical Purposes, and Medical Devices. Available from: https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.gov.pl/attachment/e48d74fb-7298-472d-adc9-ffc096d91b6d&ved=2ahUKEwj8gtPAnKWMAxXNIxAIHSimF-QQFnoECBgQAQ&usg=AOvVaw13yTFEqTqrdQq-za5Jm5vN. (Accessed on 30.03.2025)
10. Treatment of Prader-Willi Syndrome (ICD-10 Q87.1). Notice of the Minister of Health of 19 March 2025 on the List of Reimbursed Medicines, Foodstuffs for Special Medical Purposes, and Medical Devices as of 1 April 2025. Available from: https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.gov.pl/attachment/ef5919d8-51ad-49a7-9482-2a30b31d2e0f&ved=2ahUKEwjaoer7mqWMAxVKERAIHbV6LaAQFnoECBkQAQ&usg=AOvVaw00Xq3hZaKUNyBvZ1kmBvdj. (Accessed on 30.03.2025)
11. Salomon F, Cuneo RC, Hesp R, Sönksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 1989;321(26):1797-1803. doi:10.1056/NEJM198912283212605
12. Ratku B, Sebestyén V, Erdei A, Nagy E V, Szabó Z, Somodi S. Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile. Pituitary. 2022;25(2):211-228. doi:10.1007/s11102-022-01207-1
13. Grootjen LN, Trueba-Timmermans DJ, Damen L, Mahabier EF, Kerkhof GF, Hokken-Koelega ACS. Long-Term Growth Hormone Treatment of Children with PWS: The Earlier the Start, the Better the Outcomes? J Clin Med. 2022;11(9). doi:10.3390/jcm11092496
14. Carroll P V, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab. 1998;83(2):382-395. doi:10.1210/jcem.83.2.4594
15. Petriczko, Elżbieta; Korpysz, Alicja; Walczak, Mieczysław; Szalecki M. (SGA), Następstwa endokrynologiczne u dzieci urodzonych z za niską masą w stosunku do wieku ciążowego. Klin Pediatryczna. 2023;31(1):21-26. https://klinika.com.pl/produkt/kp1-2023-neonatologia/.
16. Lebl J, Lebenthal Y, Kolouskova S, et al. Metabolic impact of growth hormone treatment in short children born small for gestational age. Horm Res Paediatr. 2011;76(4):254-261. doi:10.1159/000329729
17. Hokken-Koelega A, van Pareren Y, Arends N, Boonstra V. Efficacy and Safety of Long-Term Continuous Growth Hormone Treatment of Children Born Small for Gestational Age. Horm Res Paediatr. 2004;62(suppl 3(Suppl. 3):149-154. doi:10.1159/000080518
18. Lewiński A, Smyczyńska J, Stawerska R, et al. Ogólnopolski Program Leczenia Ciężkiego Niedoboru Hormonu Wzrostu u Osób Dorosłych oraz u Młodzieży po Zakończeniu Terapii Promującej Wzrastanie. Endokrynol Pol. 2018;69(5):468-524. doi:10.5603/ep.a2018.0054
19. Miller BS, Blair JC, Rasmussen MH, et al. Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial. J Clin Endocrinol Metab. 2022;107(12):3378-3388. doi:10.1210/clinem/dgac513
20. Straetemans S, De Schepper J, Thomas M, Tenoutasse S, Beauloye V, Rooman R. Criteria for First-Year Growth Response to Growth Hormone Treatment in Prepubertal Children With Growth Hormone Deficiency: Do They Predict Poor Adult Height Outcome? Front Endocrinol (Lausanne). 2019;10(November). doi:10.3389/fendo.2019.00792
21. Bang P, Bjerknes R, Dahlgren J, et al. A comparison of different definitions of growth response in short prepubertal children treated with growth hormone. Horm Res Paediatr. 2011;75(5):335-345. doi:10.1159/000322878
22. Straetemans S, Thomas M, Craen M, Rooman R, De Schepper J. Poor growth response during the first year of growth hormone treatment in short prepubertal children with growth hormone deficiency and born small for gestational age: a comparison of different criteria. Int J Pediatr Endocrinol. 2018;2018(1):1-10. doi:10.1186/s13633-018-0064-3
23. Laron Z. Insulin-like growth factor 1 (IGF-1): A growth hormone. J Clin Pathol - Mol Pathol. 2001;54(5):311-316. doi:10.1136/mp.54.5.311
24. Wang Y, Bikle DD, Chang W. Autocrine and Paracrine Actions of IGF-I Signaling in Skeletal Development. Bone Res. 2013;1(3):249-259. doi:10.4248/BR201303003
25. Kim JH, Kim SJ, Lee J, Shin CH, Seo JY. Factors affecting IGF-I level and correlation with growth response during growth hormone treatment in LG Growth Study. PLoS One. 2021;16(7 July):1-10. doi:10.1371/journal.pone.0252283
26. Deodati A, Ferroli BB, Cianfarani S. Association between growth hormone therapy and mortality, cancer and cardiovascular risk: Systematic review and meta-analysis. Growth Horm IGF Res. 2014;24(4):105-111. doi:10.1016/J.GHIR.2014.02.001
27. Glińska M, Walczak M, Wikiera B, et al. Difficulties in Interpreting IGF-1 Levels in Short Stature Children Born Small for Gestational Age (SGA) Treated with Recombinant Human Growth Hormone (rhGH) Based on Data from Six Clinical Centers in Poland. J Clin Med. 2023;12(13). doi:10.3390/jcm12134392
28. López-Siguero JP, Martínez-Aedo MJ, Bermúdez de la Vega JA, Bosch-Muñoz J, Lechuga-Sancho AM, Villalobos T. Growth hormone treatment does not to lead to insulin resistance nor excessive rise in IGF-1 levels, while improving height in patients small for gestational age A long-term observational study. Clin Endocrinol (Oxf). 2022;96(4):558-568. doi:10.1111/cen.14626
29. Moon JE, Ko CW. Delayed Bone Age Might Accelerate the Response to Human Growth Hormone Treatment in Small for Gestational Age Children with Short Stature. Int J Endocrinol. 2019;2019. doi:10.1155/2019/8454303
30. Mentzel H-J, Vilser C, Eulenstein M, et al. Assessment of skeletal age at the wrist in children with a new ultrasound device. Pediatr Radiol. 2005;35(4):429-433. doi:10.1007/s00247-004-1385-3
31. Rachmiel M, Naugolni L, Mazor-Aronovitch K, Koren-Morag N, Bistritzer T. Bone Age Assessments by Quantitative Ultrasound (SonicBone) and Hand X-ray Based Methods are Comparable. Isr Med Assoc J. 2017;19(9):533-538.
32. Ranke MB, Lindberg A, Chatelain P, et al. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. J Clin Endocrinol Metab. 1999;84(4):1174-1183. doi:10.1210/jcem.84.4.5634
33. Ranke MB, Lindberg A, Cowell CT, et al. Prediction of response to growth hormone treatment in short children born small for gestational age: Analysis of data from KIGS (Pharmacia International Growth Database). J Clin Endocrinol Metab. 2003;88(1):125-131. doi:10.1210/jc.2002-020867
34. Ly H-J, Fors H, Nilsson S, Dahlgren J. A prediction model could foresee adequate height response in children eligible for growth hormone treatment. Acta Paediatr. 2022;111(2):346-353. doi:10.1111/apa.16070
35. Hazem A, Elamin MB, Bancos I, et al. Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur J Endocrinol. 2012;166(1):13-20. doi:10.1530/EJE-11-0558
36. Bollerslev J, Ueland T, Jørgensen AP, et al. Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol. 2006;154(4):537-543. doi:10.1530/eje.1.02125
37. Gola M, Bonadonna S, Doga M, Giustina A. Clinical review: Growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab. 2005;90(3):1864-1870. doi:10.1210/jc.2004-0545
38. Zhou H, Sun L, Zhang S, Wang Y, Wang G. Effect of long-term growth hormone replacement on glucose metabolism in adults with growth hormone deficiency: a systematic review and meta-analysis. Pituitary. 2021;24(1):130-142. doi:10.1007/s11102-020-01079-3
39. Hoffman AR, Kuntze JE, Baptista J, et al. Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89(5):2048-2056. doi:10.1210/jc.2003-030346
40. Lewitt MS. The Role of the Growth Hormone/Insulin-Like Growth Factor System in Visceral Adiposity. Biochem insights. 2017;10:1178626417703995. doi:10.1177/1178626417703995
41. Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab. 2014;99(3):852-860. doi:10.1210/jc.2013-3921
42. Hansen TB, Brixen K, Vahl N, et al. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab. 1996;81(9):3352-3359. doi:10.1210/jcem.81.9.8784096
43. Holmes SJ, Whitehouse RW, Swindell R, Economou G, Adams JE, Shalet SM. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency. Clin Endocrinol (Oxf). 1995;42(6):627-633. doi:10.1111/j.1365-2265.1995.tb02690.x
44. Yang H, Chen M, Xu H, et al. Bone mineral density in adults growth hormone deficiency with different ages of onset: a real-world retrospective study. Endocrine. 2024;85(1):347-355. doi:10.1007/s12020-024-03786-4
45. Webb SM. Measurements of quality of life in patients with growth hormone deficiency. J Endocrinol Invest. 2008;31(9 Suppl):52-55.
46. Karbownik-Lewińska M, Lewiński A, McKenna S, et al. The Polish version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) - four-stage translation and validation. Endokrynol Pol. 2008;59(5):374-384.
47. Elbornsson M, Horvath A, Götherström G, Bengtsson B-Å, Johannsson G, Svensson J. Seven years of growth hormone (GH) replacement improves quality of life in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol. 2017;176(2):99-109. doi:10.1530/EJE-16-0875
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Agata Kotkowiak, Mikołaj Łabuda, Agnieszka Szema , Jakub Sikora, Karolina Knychalska, Klaudia Królikowska, Aleksandra Słojewska, Teresa Sowińska, Oliwia Mentel, Adrianna Bogucka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 177
Number of citations: 0
